tradmap

GPCR Earnings Structure Therapeutics Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$6 -$3 $0 2022 2023 2024 2025
EPS
Net income (annual)
-$141M -$71M $0 2022 2023 2024 2025
Net income
Return on equity (annual)
-20% 12% 45% 0% 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$4 -$2 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$106M -$37M $33M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-12% -5% 2% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–18 of 18
Q2 20262026-06-30-0.842026-08-0610-Q
Q1 20262026-03-31-0.352026-05-0710-Q
FY 20252025-12-31-0.802026-02-2610-K
Q3 20252025-09-30-1.002025-11-0610-Q
Q2 20262025-06-30-0.632026-08-0610-Q
Q1 20262025-03-31-0.272026-05-0710-Q
FY 20252024-12-31-0.782026-02-2610-K
Q3 20252024-09-30-0.562025-11-0610-Q
Q2 20252024-06-30-0.362025-08-0610-Q
Q1 20252024-03-31-0.192025-05-0810-Q
FY 20252023-12-31-0.812026-02-2610-K
Q3 20242023-09-30-0.652024-11-1310-Q
Q2 20242023-06-30-0.442024-08-0810-Q
Q1 20242023-03-31-0.252024-05-0910-Q
FY 20232022-12-31-5.512024-03-0810-K
Q3 20232022-09-30-4.342023-11-1710-Q
Q2 20232022-06-30-3.092023-08-1010-Q
Q1 20232022-03-31-1.442023-05-1110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.